MusclePharm Signs Multi-Year Endorsement Deal With Johnny Manziel

DENVER, Aug. 4, 2014 /PRNewswire/ -- MusclePharm Corporation (OTCQB: MSLP), a scientifically driven, performance-lifestyle sports nutrition company, is proud to announce it has signed a multi-year endorsement deal with former Heisman Trophy winner and NFL first-round draft pick Johnny Manziel.

Manziel, who is also known by his nickname "Johnny Football," was drafted by the Cleveland Browns with the 22^nd pick in the first round of the 2014 NFL Draft. In 2012, the Texas A&M Aggies first season in the SEC, Manziel debuted for the team as a redshirt freshman. He broke numerous NCAA Division I FBS as well as SEC records, including becoming the first freshman and only the fifth player in NCAA history to pass for 3000 yards and rush for 1000 yards in a single season.  At the end of the regular season, he became the first freshman to win the Heisman Trophy, as well as the Manning Award and the Davey O'Brien National Quarterback Award.

"I'm proud to join a lineup of competitive athletes from around the world who know MusclePharm as the top sports nutrition innovator and industry leader," said Manziel.  "Top athletes know that MusclePharm has what they need to perform at their very best."

In addition to Manziel, MusclePharm's stable of endorsers includes Tiger Woods, Arnold Schwarzenegger, and professional football players Eric Decker and Colin Kaepernick. MusclePharm is also the Official Supplement Provider of Ultimate Fighting Championship® (UFC) and USA Wrestling.

Commenting on the announcement, MusclePharm Founder & CEO, Brad Pyatt, stated, "Manziel is an electrifying athlete and a proven winner with a rare and dynamic athleticism. His work ethic combined with his relentless competitive drive make him an ideal fit for the MusclePharm brand. We are excited for the future."

About MusclePharm

MusclePharm® is a scientifically driven, performance-lifestyle company that currently develops, manufactures, markets and distributes branded nutritional supplements. The company offers a complete range of powders, capsules, tablets and gels. Its portfolio of recognized brands, including MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™ and FitMiss®, are marketed and sold in more than 110 countries and available in over 35,000 retail outlets globally. These clinically-proven and scientific nutritional supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit www.musclepharm.com.

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Photo - http://photos.prnewswire.com/prnh/20140804/132838

SOURCE MusclePharm Corporation